TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26670466

Group type: EXPERIMENTAL
Intervention: rindopepimut plus bevacizumab
Number of subjects: 0
Study: 26670630

Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Second PDT treatment
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High-density subthreshold diode micropulse laser (HSML) therapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Overall treatment strategy (PDT + HSML)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: First half-dose PDT treatment
Number of subjects: 59
Study: 26670913

Group type: EXPERIMENTAL
Intervention: Video-based STI/HIV prevention intervention
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Discussion of risks with potentially exposed partners
Number of subjects: 450
Study: 26671110

Group type: EXPERIMENTAL
Intervention: Retinoblastoma patients (TRb cohort)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Retinoblastoma patients (non-TRb cohort)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 80
Study: 26672022

Group type: EXPERIMENTAL
Intervention: Digital imaging with ROP examination at discharge
Number of subjects: 650

Group type: COMPARATOR
Intervention: ROP examination-only strategy
Number of subjects: 650
Study: 26672094

Group type: EXPERIMENTAL
Intervention: 75-g oral glucose tolerance test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isoglycemic intravenous glucose infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 20
Study: 26672496

Group type: EXPERIMENTAL
Intervention: Dietary restriction of propiogenic amino acids and carnitine supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 0
Study: 26672609

Group type: EXPERIMENTAL
Intervention: Tooth loss level (no teeth)
Number of subjects: 15456

Group type: EXPERIMENTAL
Intervention: Tooth loss level (increase in level)
Number of subjects: 15456
Study: 26672987

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (1.9 g/d EPA and 1.5 g/d DHA for six weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 12
Study: 26673413

Group type: EXPERIMENTAL
Intervention: AmpliSeq
Number of subjects: 2
Study: 26673787

Group type: EXPERIMENTAL
Intervention: Horror movie
Number of subjects: 24

Group type: COMPARATOR
Intervention: Educational movie
Number of subjects: 24
Study: 26674132

Group type: EXPERIMENTAL
Intervention: Combination immunotherapy trial utilizing MEDI4736 and MEDI0680
Number of subjects: 1
Study: 26674498

Group type: EXPERIMENTAL
Intervention: 10-week exercise programme with a personal trainer
Number of subjects: 0
Study: 26674520

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily for one year
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 250
Study: 26674763

Group type: EXPERIMENTAL
Intervention: Controlled phytoene diet (1-5 mg/d) for 42 days, with 3.2 mg (13)C-phytoene consumed on day 14.
Number of subjects: 4
Study: 26675348

Group type: EXPERIMENTAL
Intervention: Recombinant human IL-7 (rhIL-7) administered as 3 subcutaneous doses per week.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injection site reactions and hypersensitivity reaction to IL-7.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 26675764

Group type: EXPERIMENTAL
Intervention: Doubly labeled water (DLW) method for measuring total energy expenditure (TEE) in SBS patients.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Doubly labeled water (DLW) method for measuring total energy expenditure (TEE) in non-SBS controls.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of measured TEE between SBS and non-SBS groups.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Predicted TEE using the Escott-Stump equation for both groups.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Indirect calorimetry for measuring resting energy expenditure.
Number of subjects: 22
Study: 26675775

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 16
Study: 26675779

Group type: EXPERIMENTAL
Intervention: Mothers taking vitamin D supplements
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Foremilk
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Hindmilk
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Infant daily intake through breast milk of vitamin D
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Breast milk vitamin D supply
Number of subjects: 107
Study: 26676711

Group type: EXPERIMENTAL
Intervention: Nonoperative management (24 hours inpatient observation with IV antibiotics, followed by 10 days of oral antibiotics)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Surgery (urgent appendectomy)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Nonoperative management
Number of subjects: 102

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 102
Study: 26678502

Group type: COMPARATOR
Intervention: <3 h/day television viewing
Number of subjects: 165087

Group type: EXPERIMENTAL
Intervention: 5+ h/day television viewing
Number of subjects: 165087

Group type: EXPERIMENTAL
Intervention: Decreased television viewing from 5+ h/day to 3-4 h/day
Number of subjects: 165087

Group type: EXPERIMENTAL
Intervention: Decreased television viewing to <3 h/day
Number of subjects: 165087

Group type: EXPERIMENTAL
Intervention: Increased television viewing to 3-4 h/day
Number of subjects: 165087

Group type: EXPERIMENTAL
Intervention: Increased television viewing to 5+ h/day
Number of subjects: 165087

Group type: EXPERIMENTAL
Intervention: Consistently active and watched <3 h/day of television
Number of subjects: 165087
Study: 26678639

Group type: EXPERIMENTAL
Intervention: N-terminal-pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 5592

Group type: EXPERIMENTAL
Intervention: Cardiac troponin T (TnT)
Number of subjects: 5592

Group type: EXPERIMENTAL
Intervention: Change in NT-proBNP
Number of subjects: 5592
Study: 26678646

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy (varied by physician discretion)
Number of subjects: 2500
Study: 26678657

Group type: EXPERIMENTAL
Intervention: Genetic testing and histopathological techniques
Number of subjects: 1
Study: 26678660

Group type: EXPERIMENTAL
Intervention: Volumetric radiosurgery (VRS) with 47.5 Gy in 5 fractions
Number of subjects: 60
Study: 26678684

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 334
Study: 26678860

Group type: EXPERIMENTAL
Intervention: SNOT-22 subdomains and LK variables
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Weighted combination of symptom domains and endoscopic attributes
Number of subjects: 629
Study: 26679295

Group type: EXPERIMENTAL
Intervention: GAD Online (unguided self-help intervention)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lantern (guided self-help intervention)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: GAD Online and Lantern
Number of subjects: 300
Study: 26679868

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*01 allele
Number of subjects: 10228

Group type: EXPERIMENTAL
Intervention: BTNL2 blocking in T-cell stimulation assays
Number of subjects: 10228
Study: 26680241

Group type: EXPERIMENTAL
Intervention: Unplanned rehospitalizations (inpatient or observation status) within 30 days after discharge
Number of subjects: 12312

Group type: EXPERIMENTAL
Intervention: Unplanned rehospitalizations for cardiovascular reasons
Number of subjects: 12312

Group type: EXPERIMENTAL
Intervention: Variation in hospital rates of 30-day unplanned rehospitalization
Number of subjects: 12312

Group type: EXPERIMENTAL
Intervention: Factors associated with unplanned rehospitalization
Number of subjects: 12312
Study: 26681111

Group type: EXPERIMENTAL
Intervention: HYD 20-120 mg daily
Number of subjects: 106
Study: 26681124

Group type: EXPERIMENTAL
Intervention: Impella RP device
Number of subjects: 30
Study: 26681676

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day until progression or intolerance
Number of subjects: 134
Study: 26681716

Group type: EXPERIMENTAL
Intervention: A1C
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Fructosamine
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: GA
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: A1C combined with Fructosamine
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: A1C combined with GA
Number of subjects: 217
Study: 26681756

Group type: EXPERIMENTAL
Intervention: PZ-128 (0.01-2 mg/kg) administered by 1 to 2 hours continuous intravenous infusion
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PZ-128 (0.5 mg/kg) with aspirin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PZ-128 (0.5 mg/kg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PZ-128
Number of subjects: 31
Study: 26682038

Group type: EXPERIMENTAL
Intervention: Sublingual allergy immunotherapy tablet (GRAZAX®) plus standard treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo plus standard treatment
Number of subjects: 50
Study: 26682232

Group type: EXPERIMENTAL
Intervention: Platform users (active and curious)
Number of subjects: 633

Group type: COMPARATOR
Intervention: Nonusers
Number of subjects: 633
Study: 26684009

Group type: EXPERIMENTAL
Intervention: Absorb Everolimus-Eluting BVS (Abbott Vascular, Santa Clara, CA, USA)
Number of subjects: 0
Study: 26684198

Group type: EXPERIMENTAL
Intervention: Radiotherapy and concomitant-adjuvant temozolomide chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive functioning assessments, specific blood biomarkers measures, and magnetic resonance imagery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New cognitive test
Number of subjects: 0
Study: 26684274

Group type: EXPERIMENTAL
Intervention: Serum UA levels (per SD increase)
Number of subjects: 5074

Group type: EXPERIMENTAL
Intervention: Baseline UA levels
Number of subjects: 5074
Study: 26684818

Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 819

Group type: COMPARATOR
Intervention: ZDV
Number of subjects: 819
Study: 26684868

Group type: EXPERIMENTAL
Intervention: Alcohol use disorder (AUD) participants
Number of subjects: 48

Group type: COMPARATOR
Intervention: Substance use disorder (SUD) participants
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both AUD and SUD participants
Number of subjects: 48
Study: 26684894

Group type: EXPERIMENTAL
Intervention: Perceived built environment variables in neighborhoods with higher residential density
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Perceived neighborhood environment with friends or acquaintances similar in demographic characteristics
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Mixed model regression analysis
Number of subjects: 1600
Study: 26685073

Group type: EXPERIMENTAL
Intervention: Fontan operation
Number of subjects: 408
Study: 26685704

Group type: COMPARATOR
Intervention: Control arm of the VIVIANE study
Number of subjects: 2838
Study: 26685770

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50 mg/kg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 100 mg/kg
Number of subjects: 96
Study: 26685936

Group type: EXPERIMENTAL
Intervention: Ovation® Prime stent graft under least invasive conditions using a fast-track protocol
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard EVAR (not explicitly defined in the abstract)
Number of subjects: 250
Study: 26686257

Group type: EXPERIMENTAL
Intervention: Limited compression ultrasonography (group 2)
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Extended whole-leg compression ultrasonography (group 3)
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Group 1 (DVT ruled out)
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Group 2 (DVT ruled out)
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Group 3 (DVT ruled out)
Number of subjects: 1162
Study: 26686256

Group type: EXPERIMENTAL
Intervention: Thalidomide at a starting dose of 50 mg/day, increased by 50 mg/day increments every 4 weeks up to a maximum of 200 mg/day if no response was seen.
Number of subjects: 31
Study: 26687320

Group type: EXPERIMENTAL
Intervention: Zidovudine-containing regimens
Number of subjects: 16304

Group type: COMPARATOR
Intervention: Non-zidovudine antiretroviral regimens
Number of subjects: 16304
Study: 26687423

Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m² once a day for days 1-5 of each 28-day cycle and lenalidomide (initially 50 mg for 10 days, later adjusted to 25 mg for 5 days)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Azacitidine and lenalidomide combination
Number of subjects: 88
Study: 26687796

Group type: EXPERIMENTAL
Intervention: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 1 (2.5 mCi/m²)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 2 (5.0 mCi/m²)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 3 (7.5 mCi/m²)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 4 (10.0 mCi/m²)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: (90)Y-DOTA-epratuzumab radioimmunotherapy at all levels
Number of subjects: 17
Study: 26687956

Group type: EXPERIMENTAL
Intervention: HbAS (sickle cell trait)
Number of subjects: 1543

Group type: EXPERIMENTAL
Intervention: G6PD A-/A- homozygous girls
Number of subjects: 1543

Group type: EXPERIMENTAL
Intervention: HbAC
Number of subjects: 1543

Group type: EXPERIMENTAL
Intervention: HbAS
Number of subjects: 1543
Study: 26687958

Group type: EXPERIMENTAL
Intervention: Romidepsin 12 mg/m(2) combined with CHOP (intravenous cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.4 mg/m(2) [maximum 2 mg], oral prednisone 40 mg/m(2))
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Romidepsin 10 mg/m(2) combined with CHOP
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Romidepsin 8 mg/m(2) combined with CHOP
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Romidepsin 12 mg/m(2) combined with CHOP
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Romidepsin combined with CHOP
Number of subjects: 37
Study: 26688132

Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 0
Study: 26688485

Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg oral three times a week and bortezomib 1.3 mg/m² intravenous two times a week for 2 of 3 weeks for up to eight cycles.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Panobinostat and bortezomib combination treatment
Number of subjects: 25
Study: 26688487

Group type: EXPERIMENTAL
Intervention: PF-04449913 at 80 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PF-04449913 at 600 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PF-04449913 (all doses)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PF-04449913 at MTD (400 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Recommended phase 2 dose
Number of subjects: 47
Study: 26688733

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study: 26688734

Group type: EXPERIMENTAL
Intervention: Walnut-included diet (56 g providing 366 kcal per day)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Walnut-excluded diet
Number of subjects: 112
Study: 26688787

Group type: EXPERIMENTAL
Intervention: Educational plan for retigabine (retigabine Physician's Guide)
Number of subjects: 294
Study: 26689767

Group type: EXPERIMENTAL
Intervention: Boceprevir, PegIFN, and RBV for 12 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Historical controls treated with PegIFN and RBV for 24 weeks
Number of subjects: 57
Study: 26690287

Group type: EXPERIMENTAL
Intervention: Phosphorus supplementation
Number of subjects: 63
Study: 26690712

Group type: EXPERIMENTAL
Intervention: DCE-MRI in MGUS patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CT in SMM patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: DCE-MRI in SMM patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT in MM patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: DCE-MRI in MM patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: NaF-PET/CT in MM patients
Number of subjects: 46
Study: 26690793

Group type: EXPERIMENTAL
Intervention: Biodegradable polydioxanone stents
Number of subjects: 4
Study: 26691513

Group type: EXPERIMENTAL
Intervention: Intraoperative trans-fontanellar cerebral ultrasonography (TFCU)
Number of subjects: 35
Study: 26691547

Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and Sofosbuvir (400 mg) administered as one tablet once daily for 12 weeks
Number of subjects: 70
Study: 26692015

Group type: EXPERIMENTAL
Intervention: 12 regional, standardised, sports club based exercise sessions
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Informative written brochure
Number of subjects: 60000
Study: 26692236

Group type: EXPERIMENTAL
Intervention: High Contact-Moderate Conflict-Moderate Support
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Low Contact-Moderate Conflict-Low Support
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: High Conflict-Moderate Contact-Moderate Support
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Low Conflict-Moderate Contact-Moderate Support
Number of subjects: 240
Study: 26692248

Group type: EXPERIMENTAL
Intervention: E-XLPE liner
Number of subjects: 977

Group type: COMPARATOR
Intervention: AXL liner
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: E-XLPE and AXL liners
Number of subjects: 977
Study: 26692255

Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (SRIs)
Number of subjects: 263

Group type: COMPARATOR
Intervention: No SRI exposure (Control)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (SRIs) at delivery
Number of subjects: 263

Group type: COMPARATOR
Intervention: No SRI exposure at delivery (Control)
Number of subjects: 263
Study: 26692553

Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 9203

Group type: EXPERIMENTAL
Intervention: Weight
Number of subjects: 9203

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 9203

Group type: EXPERIMENTAL
Intervention: BSA
Number of subjects: 9203
Study: 26693033

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study: 26693034

Group type: EXPERIMENTAL
Intervention: Vilazodone 10 mg/d
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vilazodone 20 mg/d
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/d
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vilazodone (all doses)
Number of subjects: 70
Study: 26693035

Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation (EECP) therapy, 260 mm Hg pressure, 60 minutes, 5 days a week for 7 weeks (35 sessions)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EECP therapy
Number of subjects: 50
Study: 26693967

Group type: EXPERIMENTAL
Intervention: Promillekoll app (real-time estimated eBAC calculation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PartyPlanner app (real-time eBAC calculation with planning and follow-up functions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TeleCoach app (skills training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 0
Study: 26694975

Group type: EXPERIMENTAL
Intervention: Pregabalin (300-450 mg/day)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 26695065

Group type: EXPERIMENTAL
Intervention: Gadofosveset trisodium injection using a dual-injection protocol (70% bolus / 30% slow infusion)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gadofosveset trisodium injection using a dual-injection protocol (60% bolus / 40% slow infusion)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gadofosveset injection optimized for lowest intravascular T1 time
Number of subjects: 14
Study: 26695349

Group type: EXPERIMENTAL
Intervention: MSN (extended-release morphine sulfate with sequestered naltrexone hydrochloride)
Number of subjects: 1012
Study: 26695837

Group type: EXPERIMENTAL
Intervention: PAs in charge (100% PA)
Number of subjects: 179

Group type: COMPARATOR
Intervention: MDs in charge (100% MD)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Mixed PA/MR model
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Medical specialists in charge (100% MS)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Medical residents in charge (100% MR)
Number of subjects: 179
Study: 26695935

Group type: EXPERIMENTAL
Intervention: CART based on five variables (baseline dyspnea, cardiac disease, paradoxical breathing or use of accessory inspiratory muscles, age, Glasgow Coma Scale score)
Number of subjects: 2487

Group type: EXPERIMENTAL
Intervention: CART improved by adding the Charlson Comorbidity Index
Number of subjects: 2487

Group type: EXPERIMENTAL
Intervention: CART based on five variables
Number of subjects: 2487

Group type: EXPERIMENTAL
Intervention: CART
Number of subjects: 2487
Study: 26696388

Group type: EXPERIMENTAL
Intervention: HIV-infected women with reduced ovarian reserve (undetectable AMH)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Premenopausal women with measurable AMH
Number of subjects: 74
Study: 26696455

Group type: EXPERIMENTAL
Intervention: DANUBIO balloon inflation after Nile PAX stent placement
Number of subjects: 52
Study: 26696749

Group type: EXPERIMENTAL
Intervention: Panobinostat treatment
Number of subjects: 0
Study: 26696953

Group type: EXPERIMENTAL
Intervention: SUDEP Risk Inventory (SUDEP-7)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV)
Number of subjects: 25
Study: 26697218

Group type: EXPERIMENTAL
Intervention: Facebook-delivered lifestyle counselling and monitoring of physical activity (Fb + Act, n = 15)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Facebook-delivered lifestyle counselling without self-monitoring (Fb, n = 16)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 46
Study: 26698225

Group type: EXPERIMENTAL
Intervention: Observational study
Number of subjects: 5000